Clear Search

Showing 3 result for “Martin D”.

September 2023

乾癬性関節炎に対するTYK2/JAK1 阻害薬, ブレポシチニブの有効性と安全性: フェーズIIb 無作為化対照試験

Arthritis Rheumatol. 2023;75(8):1370–1380 doi: 10.1002/art.42519

Phase IIb study of brepocitinib in patients with PsA concludes that treatment with brepocitinib 30 mg and 60 mg QD, was superior to placebo at reducing signs and symptoms of PsA and was well-tolerated over 52 weeks.


December 2022


RMD Open. 2022;8(2):e002571 doi: 10.1136/rmdopen-2022-002571

Weitz, et al. analyse 291 protein biomarkers and three genetic markers and do not identify a clear mechanistic explanation for higher rates of venous thromboembolism (VTE) with tofacitinib in the ORAL Surveillance study.


August 2021

欧州に多いCD83近傍のバリアントとアジアに多いIL17RB近傍バリアントが、トファシチニブにおける帯状疱疹リスクに及ぼす影響: GWAS研究のメタ解析

Arthritis Rheumatol. 2021;73(7):1155–66

Genetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased herpes zoster (HZ) risk.It is well known that HZ risk is elevated in subjects with RA compared with the general population, and that treatment with JAK inhibitors may result in increased risks compared with TNFi and other bDMARD treatments. To this end, Bing, et al. used genome-wide association studies to identify genetic factors associated with an increased risk/faster onset of HZ ...